Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation

Virus Research

Volumn 52, Issue 1, 1997, Pages 43-50

  Vialat, Pierre ^a   Muller, Rolf ^a,b   Vu, Thuy Hang ^a   Prehaud, Christophe ^a   Bouloy, Michèle ^a  

^a INSTITUT PASTEUR   (France)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Attenuation; Genome; Mapping; Mutations; Rift Vally fever

Indexed keywords

VIRUS RNA;

ARTICLE; GENE MAPPING; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; VIRUS ATTENUATION; VIRUS GENOME; VIRUS MUTATION;

ANIMALS; CERCOPITHECUS AETHIOPS; DNA MUTATIONAL ANALYSIS; GENOME, VIRAL; MUTATION; POLYMERASE CHAIN REACTION; RIFT VALLEY FEVER VIRUS; VERO CELLS; VIRAL PROTEINS; VIRULENCE;

EID: 0031451694     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(97)00097-X     Document Type: Article

References (42)

1. Albarino, C.G., Ghiringhelli, P.D., Posik, D.M., Lozano, M.E., Ambrosio, A.M., Sanchez, A., Romanoswski, V., 1997. Molecular characterization of the attenuated junin virus strains. J. Gen. Virol. 78, 1605-1610.
2. Ball, J.M., Tian, P., Zeng, C.Q., Morris, A.P., Estes, M.K., 1996. Age-dependent diarrhea induced by a rotaviral non-structural glycoprotein. Science 272, 101-104.
3. Caplen, H., Peters, C.J., Bishop, D.H.L., 1985. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 66, 2271-2277.
4. Davis, N.L., Brown, K.W., Greenwald, G.F., Zajac, A.J., Zacny, V.L., Smith, J.F., Johnston, R.E., 1995. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212, 102-110.
5. Dubuisson, J., Lustig, S., Ruggli, N., Akov, Y., Rice, C.M., 1997. Genetic determinants of Sindbis virus neuroinvasiveness. J. Virol. 71, 2636-2646.
6. Flamand, A., 1992. Modern approaches to the development of attenuated virus strains. In: Isaacson, R.E. (Ed.), Library of Congress Cataloging, New York, pp. 19-47.
7. Giorgi, C., 1996. Molecular biology of phleboviruses. In: Elliott, R.M. (Ed.), The Bunyaviridae, Plenum, New York, pp. 105-123.
8. Giorgi, C., Accardi, L., Nicoletti, L., Gro, M.C., Takehara, K., Hilditch, C., Morikawa, S., Bishop, D.H., 1991. Sequences and coding strategies of the S RNAs of Toscana and Rift Valley fever viruses compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses. Virology 180, 738-753.
9. Gonzalez-Scarano, F., Nathanson, N., 1996. Bunyaviridae. In: Fields, B.N., Knipe, D.M., Howley, P.M. et al. (Eds.), Fields' Virology, Lippincott-Raven, Philadelphia, pp. 1473-1504.
10. Hahn, C.S., Dalrymple, J.M., Strauss, J.H., Rice, C.M., 1987. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl. Acad. Sci. USA 84, 2019-2023.
11. Holzmann, H., Heinz, F.X., Mandl, C.W., Guirakhoo, F., Kunz, C., 1990. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J. Virol. 64, 5156-5159.
12. Jennings, A.D., Gibson, C.A., Miller, B.R., Mathews, J.H., Mitchell, C.J., Roehrig, J.T., Wood, D.J., Taffs, F., Sil, B.K., Whitby, S.N., et al., 1994. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169, 512-518.
13. Kakach, L.T., Wasmoen, T.L., Collett, M.S., 1988. Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. J. Virol. 62, 826-833.
14. Kakach, L.T., Suzich, J.A., Collett, M.S., 1989. Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation. Virology 170, 505-510.
15. Kawamura, N., Kohara, M., Abe, S., Komatsu, T., Tago, K., Arita, M., Nomoto, A., 1989. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63, 1302-1309.
16. Keegan, K., Collett, M.S., 1986. Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J. Virol. 58, 263-270.
17. Klenk, H.D., Rott, R., 1988. The molecular biology of influenza virus pathogenicity. Adv. Virus Res. 34, 247-281.
18. Li, S., Schulman, J., Itamura, S., Palese, P., 1993. Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. J. Virol. 67, 6667-6673.
19. Lopez, N., Muller, R., Prehaud, C., Bouloy, M., 1995. The L protein of Rift Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic genome-like RNA molecules. J. Virol. 69, 1-9.
20. Matloubian, M., Kolhekar, S.R., Somasundaram, T., Ahmed, R., 1993. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 67, 7340-7349.
21. Morrill, J.C., Carpenter, L., Taylor, D., Ramsburg, H.H., Quance, J., Peters, C.J., 1991. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 9, 35-41.
22. Morrill, J.C., McClain, D.J., 1996. Epidemiology and pathogenesis of Rift valley fever and other phleboviruses. In: Elliott, R.M. (Ed.), The Viruses, Plenum, New York, pp. 281-290.
23. Muller, R., Argentini, C., Bouloy, M., Prehaud, C., Bishop, D.H., 1991. Completion of the genome sequence of Rift Valley fever phlebovirus indicates that the L RNA is negative sense and codes for a putative transcriptase-replicase. Nucleic Acids Res. 19, 5433.
24. Muller, R., Poch, O., Delarue, M., Bishop, D.H., Bouloy, M., 1994. Rift Valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J. Gen. Virol. 75, 1345-1352.
25. Muller, R., Saluzzo, J.F., Lopez, N., Dreier, T., Turell, M., Smith, J., Bouloy, M., 1995. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med. Hyg. 53, 405-411.
26. Murphy, F.A., Fauquet, C.M., Bishop, D.H.L., Ghabrial, S.A., Jarvis, A.W., Martelli, G.P., Mayo, M.A., Summers, M.D., 1995. Family Bunyaviridae. In: The International Committee on Taxonomy of Viruses (Eds.), Sixth Report. Virus Taxonomy. Classification and Nomenclature of Viruses. Springer-Verlag, Wien, pp. 300-315.
27. Prehaud, C., Coulon, P., La Fay, F., Thiers, C., Flamand, A., 1988. Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J. Virol. 62, 1-7.
28. Rikkonen, M., 1996. Functional significance of the nuclear-targeting and NTP-binding motifs of Semliki Forest virus nonstructural protein nsP2. Virology 218, 352-361.
29. Sail, A.A., Zeller, H., Zanotto, P.M., Billecocq, A., Vialat, P., Prehaud, C., Yadani, F., Bouloy, M., 1997. Rift Valley fever virus: the nonstructural S segment coded (NSs) protein as a target to evaluate genetic variability and its role in pathogenesis. In: Dodet, S.J.F., Dodet, B. (Eds.), Factors in the Emergence of Arbovirus Diseases, Elsevier, Paris, pp. 265-271.
30. Saluzzo, J.F., Smith, J.F., 1990. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 8, 369-375.
31. Schmaljohn, C., 1994. Prospects for Vaccines to control viruses in the family Bunyaviridae. Med. Virol. 4, 185-196.
32. Schmaljohn, C.S., 1996. Bunyaviridae: The viruses and their replication. In: Fields, B.N., Knipe, D.M., Howley, P.M. et al. (Eds.), Fields Virology. Lippincott-Raven, Philadelphia.
33. Shi, P.-Y., Li, W., Brinton, M., 1996. Cell proteins bind specifically to West Nile virus minus-strand 3′ stem-loop RNA. J. Virol. 70, 6278-6287.
34. Smithburn, K.C., 1949. Rift valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br. J. Exp. Pathol. 30, 1-16.
35. Snyder, M.H., Betts, R.F., De Borde, D., Tierney, E.L., Clements, M.L., Herrington, D., Sears, S.D., Dolin, R., Maassab, H.F., Murphy, B.R., 1988. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J. Virol. 62, 488-495.
36. Struthers, J.K., Swanepoel, R., Shepherd, S.P., 1984. Protein synthesis in Rift Valley fever virus-infected cells. Virology 134, 118-124.
37. Subbarao, E.K., Park, E.J., Lawson, C.M., Chen, A.Y., Murphy, B.R., 1995. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. J. Virol. 69, 5969-5977.
38. Suzich, J.A., Kakach, L.T., Collett, M.S., 1990. Expression strategy of a phlebovirus: Biogenesis of proteins from the Rift Valley fever virus M segment. J. Virol. 64, 1549-1555.
39. Takehara, K., Min, M.K., Battles, J.K., Sugiyama, K., Emery, V.C., Dalrymple, J.M., Bishop, D.H.L., 1989. Identification of mutations in the M RNA of a candidate vaccine strain of Rift Valley fever virus. Virology 169, 452-457.
40. Wasmoen, T.L., Kakach, L.T., Collett, M.S., 1988. Rift Valley fever virus M segment: cellular localization of M segment-encoded proteins. Virology 166, 275-280.
41. Wilson, S.M., Clegg, J.C., 1991. Sequence analysis of the S RNA of the African arenavirus Mopeia: an unusual secondary structure feature in the intergenic region. Virology 180, 543-552.
42. Zeller, H.G., Fontenille, D., Traore-Lamizana, M., Thiongane, Y., Digoutte, J.P., 1997. Enzootic activity of Rift Valley fever virus in Senegal. Am. J. Trop. Med. Hyg. 56, 265-272.